In-Vitro and In-Vivo Models to Study the Activity of Antifungals against Aspergillus

Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies.

“…Four strains of Rhizopus (class Zygomycetes, order Mucorales, family Mucoraceae), were studied, including 2 ofRhizopus microsporus var. rhizopodiformis (R. microsporus) and 2 ofRhizopus arrhizus (formerly called Rhizopus oryzae) (15 [17][18][19][20].…”

“…Eluate containing spores was washed twice with water and concentrated by centrifugation to obtain a suspension free ofhyphal fragments which contained about I07 spores/ml, as estimated with a Burker hemocytometer; spores were stored at 4°C in the presence of penicillin and streptomycin at 30 and 70 gg/ml, respectively (21). Culture conditions of the non-Zygomycete strains were as previously reported (17,19).…”

“…For experimental aspergillosis, four different doses were studied. 12 infected guinea pigs were used for each experiment: 6 controls and 6 others treated with DFO (100 mg/kg in 0.5 ml of saline, injected intramuscularly during four successive days, starting 24 (17)(18)(19)(20).…”

Oral and parenteral therapy with saperconazole (R 66905) of invasive aspergillosis in normal and immunocompromised animals

“…The higher pH of this medium may also allow a higher concentration of active nonprotonated drug (18 (9,17). Itraconazole is a potent antiaspergillar triazole that can be administered orally and parenterally (10,11,13). Ketoconazole and fluconazole appeared to be only marginally active, whereas terbinafine is not active (12).…”

“…Systemic disseminated aspergillosis in the guinea pig is a reliable model that allows good extrapolation from the experimental infection to the natural disease in humans and animals (2,11). An inoculum of 25,000 spores of A. fumigatus per g of body weight of guinea pigs infected i.v.…”